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REPORT
Genomewide Linkage Screen for Waldenstro¨m
Macroglobulinemia Susceptibility Loci in High-Risk Families
Mary L. McMaster, Lynn R. Goldin, Yan Bai, Monica Ter-Minassian, Stefan Boehringer,
Therese R. Giambarresi, Linda G. Vasquez, and Margaret A. Tucker
Waldenstro¨m macroglobulinemia (WM), a distinctive subtype of non-Hodgkin lymphoma that features overproduction
of immunoglobulin M (IgM), clearly has a familial component; however, no susceptibility genes have yet been identiﬁed.
We performed a genomewide linkage analysis in 11 high-risk families with WM that were informative for linkage, for a
total of 122 individuals with DNA samples, including 34 patients with WM and 10 patients with IgM monoclonal
gammopathy of undetermined signiﬁcance (IgM MGUS). We genotyped 1,058 microsatellite markers (average spacing
3.5 cM), performed both nonparametric and parametric linkage analysis, and computed both two-point and multipoint
linkage statistics. The strongest evidence of linkage was found on chromosomes 1q and 4q when patients with WM and
with IgM MGUS were both considered affected; nonparametric linkage scores were 2.5 ( ) and 3.1 ( ),Pp .0089 Pp .004
respectively. Other locations suggestive of linkage were found on chromosomes 3 and 6. Results of two-locus linkage
analysis were consistent with independent effects. The ﬁndings from this ﬁrst linkage analysis of families at high risk
for WM represent important progress toward identifying gene(s) that modulate susceptibility to WM and toward un-
derstanding its complex etiology.
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Non-Hodgkin lymphoma (NHL [MIM 605027]) is a com-
mon cancer in older adults who live in developed coun-
tries, with a lifetime risk of ∼2.0%.1 Lymphomas are het-
erogeneous in terms of pathology, risk factors, and
prognosis, and this heterogeneity has hampered efforts to
delineate the genetic determinants of disease. Walden-
stro¨m macroglobulinemia (WM [MIM 153600]) is a rare
subtype of NHL that is highly distinctive on the basis of
its hypersecretion of monoclonal immunoglobulin M
(IgM).2 The public health burden is substantially increased
by the fact that WM behaves in an indolent fashion, re-
quiring treatment for many years before patients ulti-
mately succumb to their disease. Whereas WM is rare, an
asymptomatic elevation of monoclonal IgM protein,
termed “IgM monoclonal gammopathy of undetermined
signiﬁcance” (IgM MGUS), is more common in the pop-
ulation. Patients with IgM MGUS can progress to develop
WM, at the rate of 1.5%–2% per year.3
Little is known about the contribution of either genetic
or extrinsic risk factors to the etiology of WM. Descrip-
tions of environmental associations with WM are sparse,4
and WM has not been reported in association with any
of several known extrinsic risk factors for NHL.5 Cohort
and case-control studies have shown signiﬁcant familial
clustering of NHL and Hodgkin lymphoma (HL [MIM
236000]) and also suggest coaggregation of these B-cell
tumors,6,7 and a recent population-based registry study re-
ported signiﬁcant familial risk speciﬁcally for lympho-
plasmacytic lymphoma (LPL [the histopathologic corre-
late of WM]).8 The importance of genetic factors is further
suggested by observations of familial clustering of WM.4
In addition, we and others have shown that IgM MGUS,
which may serve as a phenotypic marker of susceptibility,
can be found with careful screening in a substantial pro-
portion of ﬁrst-degree relatives of patients with WM.4,9
Identiﬁcation of inherited susceptibility genes is an im-
portant step toward determining pathway(s) that contrib-
ute to development of WM. There have been no compre-
hensive searches of the genome to identify WM-predis-
position genes, primarily because of the difﬁculty of as-
sembling cohorts of informative families. Affected families
usually have few living members withWM, because of the
late age of onset (median age is ∼65 years in large clinical
series10–12 and ∼73 years in population-based registry series
[M. L. McMaster, unpublished observations]) and the high
related mortality.
We have been accruing a cohort of high-risk families
with multiple cases of WM, for phenotypic characteriza-
tion and genetic evaluation. We studied 11 well-charac-
terized, informative high-risk families from this cohort,
by applying a whole-genome search and using densely
spaced microsatellite markers to localize predisposition
genes.
This study was conducted under institutional review
board approval, and all patients gave informed consent
for sample collection and analysis. We deﬁned WM as
follows: (1) presence of a serum monoclonal IgM com-
ponent, (2) elevated quantitative serum IgM level, and (3)
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Figure 1. A–C, Examples of informative pedigrees, illustrating
different pedigree structures among three study families. Note the
multigenerational structure (A) with male-to-male transmission
consistent with autosomal dominant inheritance. Not shown in
panel C is a second-degree cousin also affected with WM.
Table 1. Distribution of Individuals
Affected with WM, IgM MGUS, or Other
LPDs, and Pedigree Conﬁgurations among
Families with WM
No. of Patients per Family
or Pedigree Conﬁguration
No. of
Families %
WM:
2 3 27
3 1 9
4 5 45
5 1 9
Parent-offspring 7 64
Sibling-sibling  cousin 4 36
IgM MGUS:
0 5 45
1 4 36
2 2 18
Other LPDa:
0 8 73
1 3 27
2 0 0
a Includes NHL ( ), chronic lymphocytic leu-np 2
kemia ( ), HL ( ), and multiple myelomanp 1 np 0
( ) diagnosed in ﬁrst-degree relatives of patientsnp 0
with WM. Of these patients with LPD, one patient with
NHL was coded as “unaffected” and was included in
the analysis; the other patient with NHL and the pa-
tient with chronic lymphocytic leukemia were de-
ceased and were not included in the analysis, because
our ability to infer genotype was limited.
presence of a morphologically compatible lymphoproli-
ferative inﬁltrate in the bone marrow. Symptoms attrib-
utable to elevated IgM or tumor burden were not required
for diagnosis. In contrast, we deﬁned IgM MGUS as the
asymptomatic presence of a monoclonal IgM component
with elevated quantitative serum IgM level in the absence
of a morphologically identiﬁable lymphocytic inﬁltrate in
the bone marrow. We obtained original pathology mate-
rial and reports for all individuals with a reported diag-
nosis of WM, whenever possible. We evaluated all avail-
able affected individuals and their ﬁrst-degree relatives at
the National Institutes of Health or in the ﬁeld, obtaining
biospecimens from all study participants. Participants un-
derwent routine serum protein characterization by im-
munoﬁxation electrophoresis and immunoglobulinquan-
titation by nephelometry. For those relatives found to
have IgM MGUS at screening, further evaluation was rec-
ommended. Consenting relatives underwent bone mar-
row aspiration and biopsy, the results of which were re-
viewed by an experienced hematopathologist, to dis-
tinguish IgM MGUS from asymptomatic WM. At the orig-
inal screening, 18 individuals were found to have IgM
MGUS, of whom 12 consented to bone marrow exami-
nation. Of these 12 patients, 7 received a diagnosis ofWM,
and 5 received a diagnosis of IgM MGUS, on the basis of
bone marrow examination results. To be conservative, we
classiﬁed patients who declined bone marrow examina-
tion as having IgMMGUS, for the purpose of this analysis.
Eleven families were judged to be informative for linkage
analysis (see examples in ﬁg. 1). These families represent
a subset of a larger cohort of families ascertained because
of the occurrence of multiple cases of WM or the occur-
rence of a single case of WM in combination with other
B-cell disorders within individual families. We chose to
limit the current study to the most homogeneous subset,
on the basis of the following criteria: families for which
we had DNA available for genotyping from at least two
patients with WM and from additional affected and/or
unaffected ﬁrst-degree relatives who could provide ge-
notype information suitable for linkage analysis. The pres-
ence of other B-cell disorders in a given family did not
exclude the family from the study, and each of three fam-
ilies had a single member with another B-cell lympho-
proliferative disorder (LPD) (table 1). However, DNA was
available from only one of these patients with LPD; thus,
for purposes of linkage analysis, this individual was con-
sidered unaffected. A total of 122 DNA samples were avail-
able from affected and unaffected individuals, including
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Figure 2. Multipoint NPL statistics calculated by GH for chromosomes 1–22 under the narrow affection-status model, in which only
patients given a diagnosis of WM are designated as “affected,” and under the broad affection-status model, in which patients given a
diagnosis of either WM or IgM MGUS are considered affected. GH does not compute multipoint NPL scores for the X chromosome, so
statistics shown for the X chromosome are two-point LOD scores.
34 patients with WM and 10 patients with IgM MGUS.
Among the patients with WM, the level of diagnostic ac-
curacy was high, on the basis of review of pathology spec-
imens ( ; 41%), original pathology reports ( ;np 14 np 14
41%), referring physician reports ( ; 12%), a deathnp 4
certiﬁcate ( ; 3%), or a verbal report by a ﬁrst-degreenp 1
relative ( ; 3%). Table 1 describes the distribution ofnp 1
affected individuals within families. Among all patients
with WM and IgM MGUS, DNA samples were available
for 39, and genotypes could be inferred for an additional
5. These families have good power to detect linkage if there
is one major gene or if a majority of the families are seg-
regating for the same gene. Our largest family (ﬁg. 1B) by
itself has an expected LOD score 13.0, with the assump-
tion of dominant transmission of WM and IgM MGUS.
DNAwas extracted fromcryopreserved lymphocyteswith
the use of standard methods. Genotyping was conducted
under contract with deCODE Genetics as described else-
where,13 with the use of their screening set of 1,058 micro-
satellite markers containing markers from the ABI Linkage
Marker (v. 2) screening and intercalating sets and 500 cus-
tom-made markers with known allele-size distributions.
The genotype data were checked for Mendelian consis-
tency with the use of the program PEDCHECK.14 The RE-
CODE program was used to prepare the data ﬁles for anal-
ysis and to estimate allele frequencies from all founders
in the pedigrees. Additional genotype errors were detected
using the mistyping option of SimWalk2, version 2.8915–
17 In total, only a very small number of genotypes (!0.5%)
were eliminated because of either Mendelian inconsisten-
cies or high mistyping probability.
Our primary approach to screening the genome for link-
age was to compute multipoint NPL score statistics with
the use of the program Genehunter (GH).18 This is a con-
servative approach that does not rely on assumptions
about the geneticmodel. However, since the conﬁguration
of most of the families in this sample, which included our
largest andmost informative families, appeared to be com-
patible with autosomal dominant transmission of WM
and MGUS, we also used GH to compute parametric LOD
scores assuming homogeneity and LOD scores assuming
heterogeneity (HLOD), with the parameter a deﬁned as
the proportion of linked families. Thus, for parametric
LOD scores, we assumedWMor the combinedWM/MGUS
trait to be inherited as a rare dominant gene with a max-
imum penetrance of 50% and an allele frequency of 0.006.
We assumed that penetrance increased with age, and we
used age incidence rates in the population to construct
liability classes. We analyzed the data under two models
of disease classiﬁcation. For the narrow model, we as-
sumed that only those individuals who received a diag-
nosis of WM were affected and that all others were un-
affected or unknown. For the broad model, we assumed
that individuals with either WM or IgM MGUS were af-
fected and that all others were unaffected or unknown.
Because some of the pedigrees were too large for GH, the
program did eliminate some individuals from the analysis
(15 individuals from three families). Regions of the ge-
nome with GH P values .01 were followed up with NPL
analyses with the use of the program SimWalk2, to include
all individuals in the calculation. To assess interactions
among selected locations that came up positive in the
initial analysis, we used the program GH 2-locus.19 We
computed NPL scores, to avoid specifying parameters for
a two-locus disease model. To reduce calculation time, we
limited our analyses to 15-bit inheritance vectors and to
windows of 60–80 Mb around the most promising peaks
from the single-locus analysis.
NPL scores from GH for the narrow and broad affection-
status models can be seen in ﬁgure 2 for chromosomes 1–
22. The strongest evidence for linkage was found on chro-
mosomes 1, 3, 4, and 6 (ﬁg. 3). On chromosome 1, several
single-point LOD scores in the region from 203 cM to 232
cM were 12.0, with the highest-occurring score at locus
D1S205 (LOD score 2.71), under the assumption of the
narrow model. The peak signal from multipoint analysis
was at map location 207 cM, ﬂanked by loci D1S2615 and
D1S2717. There was evidence for linkage under both the
narrow and broad models, but the multipoint statistics
were higher with the assumption of the broad affection-
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Figure 3. Multipoint LOD and NPL scores under the narrow af-
fection-status model and under the broad affection-status model
for chromosomes with suggestive two-point linkage results. Cal-
culations were performed under an assumption of genetic homo-
geneity for autosomal dominant inheritance with maximum pen-
etrance of 50%. Values !2 are not shown.
status model (NPL score 2.5; ; SimWalk2Pp .0089 Pp
). The HLOD score was 1.70 ( ), indicating.004 ap 0.65
evidence of linkage from most of the families. Multipoint
analysis of chromosome 4 showed high LOD and NPL
scores under the broad model at location 173.6 cM, with
ﬂanking markers D4S2910 and D4S1539. Parametric
analyses under the narrow model showed a peak in the
same location. Under the broad model, the GH NPL score
was 3.1 ( ), LOD score was 2.5, and HLOD scorePp .004
was 2.9 ( ). However, the P value calculated byap 0.76
SimWalk2 was not signiﬁcant ( ). As can be seen inPp .07
the ﬁgure, the highest statistic is at only one locus, with
the surrounding markers showing somewhat weaker evi-
dence of linkage. On chromosome 3, an NPL score of 2.9
( ) was found at location 133 cM, ﬂanked bymark-Pp .005
ers D3S3515 and D3S1267, under the broad model. The
highest NPL statistic computed by SimWalk2 was at
D3S1558 (location at 129 cM, ). One family hadPp .018
a LOD score of 1.5 in this region, but the HLOD was only
1.1 ( ). On chromosome 6, there was a peak nearap 0.30
the q-terminal end under the broad model, with a peak
NPL score of 2.3 ( ) at location 188 cM, ﬂanked byPp .01
markers D6S297 and D6S503. The HLOD score was 1.71
( ). The highest SimWalk2 statistic was at D6S281ap 0.83
( ). There were a few other regions of the genomePp .01
where the nominal P values were !.05 under either the
narrow or the broad model (chromosomes 6, 7, 8, 9, 11,
13, 14, and X), but these may be chance ﬁndings. Two-
locus NPL scores were computed for pairwise combina-
tions of chromosomes 1, 3, and 4 and resulted inmaximal
NPL scores of 3.8 (chromosomes 1 and 3), 3.9 (chromo-
somes 1 and 4) (ﬁg. 4), and 4.1 (chromosomes 3 and 4),
in conﬁgurations consistent with independent rather than
interactive effects. The closest corresponding marker pairs
were D1S249 and D4S3030, D1S249 and D4S3030, and
D3S1267 and D4S3030, respectively.
We have conducted the ﬁrst, to our knowledge, dense-
marker genomewide screen of families at high risk for
WM. The two strongest ﬁndings are on chromosomes 1q
and 4q. These two regions have NPL or LOD scores that
are suggestive for linkage, according to the criteria of
Lander and Kruglyak.20 However, the 4q ﬁnding was less
strong when the SimWalk2 statistics were calculated, and
the strongest evidence appears to be in a narrow region.
Two additional regions on chromosome 3q (NPL score 2.9)
and 6q (NPL score 2.3) have slightly lower signiﬁcance
levels and warrant further evaluation. The heterogeneity
results indicated that ∼65% of the families show evidence
of linkage to the regions on 1, 4, and 6. The two-locus
results did not suggest interaction between the linkage
peaks, which gives further support to heterogeneity of ef-
fects. Since there are no formal tests of signiﬁcance for the
two-locus analysis, however, they should be considered
exploratory.19,21
For each of the four most-positive regions for linkage,
the evidence was always stronger with assumption of the
broad affection-status model—that is, when bothWMand
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Figure 4. Two-locus NPL scores of the regions having strongest evidence for linkage in the initial single-locus parametric and NPL
analysis. Results are shown for chromosomes 1 and 4. The arrow labeled “NPL” indicates the point associated with maximum NPL score
for the two-locus analysis. The coordinate arrows indicate where the maximum two-locus NPL scores were reached, at markers D1S249
and D4S3030 (207.07 cM and 170.81 cM, respectively).
IgM MGUS are included as “affected,” which suggests that
both conditions share a common susceptibility gene(s).
Precise prevalence rates for IgM MGUS in the general pop-
ulation are unknown, but population-based estimates sug-
gest a maximum prevalence of ∼0.5%.22 In contrast, the
frequency of IgM MGUS is increased ∼10-fold in ﬁrst-de-
gree relatives of patients with familial WM,4 and progres-
sion of IgM MGUS to WM has been shown to occur in
some families.23 These observations are consistent with
our results and suggest that the clinical spectrum in fa-
milial WM is broad.
It is worth noting that two of the regions identiﬁed here
(4q and 3q) are bounded by markers that were identiﬁed
as secondary regions of interest in a similar genomewide
linkage study of 44 families at high risk for HL.13 Whereas
the clinical and morphological spectra of WM and HL are
clearly distinct, they both are malignancies of B-cell ori-
gin,24 so it is possible that we have identiﬁed regions of
common susceptibility. We have diagnosed other LPDs in
patients in these and other families withWM that we have
studied. Both population and clinicopathological studies
suggest some familial overlap among B-cell tumors in gen-
eral (including NHL, HL, and chronic lymphocytic leu-
kemia [MIM 151400]).6,7,25–27 Furthermore, in a recent case
series, 20% of patients with familial WM reported a family
history of a B-cell malignancy other than WM.28 Within
population-based studies that have reported cross-suscep-
tibility, the relative risk is highest for the same malig-
nancy,6,7,25 suggesting that families enriched for a single
disease may provide higher power for detecting linkage to
genes with main effects. In particular, a recent registry
study calculated the familial risk for B-cell disorders
among patients with LPL and reported a standardized in-
cidence ratio of 43.4 for LPL, compared with 4.0 and 4.1
for all NHL and chronic lymphocytic leukemia, respec-
tively. In this analysis, we did not have enough data to
test whether counting individuals with other lymphopro-
liferative cancers as “affected” increases the evidence for
linkage; however, this is clearly a question that should be
addressed in future studies.
Review of current genome databases—for example,Map
Viewer (build 36.1)—reveals that each of the regions iden-
tiﬁed contains multiple potential candidate genes, includ-
ing many that are generally involved in cell-cycle control,
transcriptional regulation, apoptosis, and/or immune reg-
ulation, and others that have roles related speciﬁcally to
B cells, including cytokines, cell surface markers, and reg-
ulators of immunoglobulin gene rearrangement. Because
the pathophysiology of WM is uncertain, there could be
additional relevant candidate genes. However, none of
these genes have been identiﬁed as candidates for WM in
other studies. One would want to have stronger evidence
and narrower regions for these peaks before undertaking
a systematic screening for speciﬁc candidate genes.
Many hematologic and lymphoid malignancies are
characterized by speciﬁc cytogenetic abnormalities that
have been found to involve genes that are important in
oncogenesis. Various cytogenetic aberrations have been
reported in sporadic WM, including occasional abnor-
malities that overlap with our results.29–32 However, few of
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the reported changes involving chromosomes 1q, 4q, or
3q are recurrent, and none are characteristic of WM. The
most common recurrent cytogenetic alteration in WM,
del(6)(q21q23),32 is a nonspeciﬁc ﬁnding also seen inother
types of B-cell lymphoma. Furthermore, although several
potential candidate genes map to 6q21-q23, these loci are
25–50 cM centromeric of the peak that we identiﬁed.
Thus, it appears unlikely that the gene(s) involved in
del(6q) and seen in sporadic WM are responsible for the
predisposition to WM found in our families. We reported
elsewhere33 the characterization of a series of patientswith
familial WM—including 10 of the patients with WM in-
cluded in the genome scan reported in this article—by
standard cytogenetics, spectral karyotyping, and compar-
ative genomic hybridization. None of the cytogenetic
changes in familial WM reported by us or by others34–36
occur within any of the regions identiﬁed in this study.
There are some limitations to this study. These families
were selected to be informative for genetic-mapping stud-
ies and are not representative of WM in the general pop-
ulation. If there were substantial genetic heterogeneity,
our study would not have sufﬁcient power to detect genes.
Larger studies are required to obtain stronger evidence for
these locations, to further narrow the regions of interest,
and to resolve questions about the spectrum of pheno-
types involved, including effects due to age, gender, and
other covariates.
In summary, this study is the ﬁrst systematic genetic
analysis of familial WM to apply highly informative,
densely spacedmarkers in a whole-genome search for link-
age analysis. The results were most strongly suggestive of
linkage to regions on chromosomes 1q and 4q under the
assumption that IgM MGUS is a phenotypic marker of
susceptibility in these families. Although model-based re-
sults were consistent, our conclusions are based on non-
parametric analyses and, therefore, do not depend on par-
ticular assumptions of a genetic model. Thus, our results
can be taken as a conservative estimate of linkage to these
loci. Furthermore, ﬁndings on chromosomes 3q and 4q
overlap with regions that we have previously found to be
linked to HL.13 These data, in combination with popula-
tion and clinicopathologic data, suggest that these B-cell
disorders may share susceptibility loci. To conﬁrm and
reﬁne these results, we are actively recruiting additional
families with WM for study. Our results represent the ini-
tial step in the process of discovery of germline WM sus-
ceptibility gene(s) and delineation of the pathways that
lead to development of WM. Once the genetic determi-
nants of WM susceptibility are deﬁned, the effect of en-
vironmental factors inmodulating risk can be studied, and
more-effective treatment and prevention strategies for
WM may be developed. Finally, any genes discoveredmay
play a role in a broader spectrum of B-cell tumors.
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